

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 April 2003 (24.04.2003)

PCT

(10) International Publication Number  
**WO 03/032995 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/505**,  
A61P 25/28

MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/SE02/01911

(22) International Filing Date: 18 October 2002 (18.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:  
0103509-6 19 October 2001 (19.10.2001) SE

**Declaration under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

(71) Applicant (*for all designated States except US*): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BASUN, Hans** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **PISER, Timothy** [US/US]; AstraZeneca Wilmington, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **RAK, Ihor** [US/US]; AstraZeneca Wilmington, P.O. Box 15437, Wilmington, DE 19850-5437 (US).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

**Published:**

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

(54) Title: ROSUVASTATIN IN PRE DEMENTED STATES

(57) Abstract: Provided is a method of preventing dementia in a patient comprising administering to a patient at risk of developing dementia an effective amount of rosuvastatin or its pharmaceutically acceptable salt.



WO 03/032995 A1

## **ROSUVASTATIN IN PRE DEMENTED STATES**

### **Background of The Invention**

5 Rosuvastatin (defined herein to include its pharmaceutically acceptable salts such as for example the sodium or calcium salt, as described in U.S. Patent Number 5,260,440 in examples 1 and 7 respectively). The calcium salt of rosuvastatin is represented by the chemical name bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl)]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid]  
10 calcium salt and is the preferred compound for the invention described herein. U.S. Patent Number 5,260,440 is incorporated herein by reference. Rosuvastatin is a statin which inhibits 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase. Rosuvastatin is useful in the treatment of ailments such as hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis

15 A recent study concludes that the use of statins could substantially reduce the risk of dementia in the elderly. Zornberg *et al.*, DA. Statins and the Risk of Dementia *Lancet* 356:1627-1631 (November 11, 2000). The authors admit that what they have identified is an association and not a casual link. Treatment of hypercholesterolemia with Lovastatin was observed to result in small performance decrements on neuropsychological tests of  
20 attention and psychomotor speed. *Am J. Med.* 2000:108:538-547 (2000). Other studies have found no effect on cognitive function following treatment with statins Id. At 542. The use of Rosuvastatin for the prevention of dementia has not previously been described.

### **Summary of The Invention**

Provided herein is a method of preventing dementia in a patient comprising  
25 administering to a patient at risk of developing dementia an effective amount of rosuvastatin and the use of rosuvastatin or its pharmaceutically acceptable salt for the manufacture of a medicament for administration to a patient at risk of developing dementia.

### **Detailed Description of The Invention**

Dementia, for purposes of the present invention includes Alzheimer's disease (AD),  
30 vascular dementia and mixed cases. The early stages of dementia has to some degree been elucidated and defined. For example, studies have established a group of individuals that are at risk of developing dementia. These individuals suffer from mild cognitive

impairment (MCI). MCI refers to a clinical state wherein the individuals are memory impaired but do not meet the clinical criteria for dementia. Petersen, et al., *Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review)*, Neurology, 56:1133-1142 (2001). The criteria used to establish MCI is as follows:

- 5 1) the presence of a subjective memory complaint, preferably corroborated by an informant; 2) preserved general intellectual functioning as estimated by performance on a vocabulary test; 3) demonstration of a memory impairment by cognitive testing; 4) intact activities of daily living; and 5) absence of dementia.

Another group of individuals that are at risk for developing dementia are those in a  
10 pre-demented state found with age associated cognitive decline (AACD) which is generally defined by a decline of more than one standard deviation in any are of cognitive functioning in comparison with age matched controls. K. Ritchie et al., *Classification criteria for mild cognitive impairment: A population-based validation study*, Neurology 56:37-42 (2001). Ritchie *et al.*, argues that AACD has a higher predictive validity for  
15 dementia onset. Id. at 40.

A further pre-demented condition may be determined by examining the following criteria: 1) subjective cognitive complaint: involves-substantial cognitive impairment reported by patient and proxy and it may include one or more cognitive domains, but not necessarily memory; 2) objective cognitive impairment: established by a battery of  
20 neuropsychological tests, preferably those that can be followed for at least 2 years and the tests should cover memory, attention, visuospatial abilities, and executive function; 3) global cognition scale: a Global Deterioration Scale (GDS) suggested with a score of 3; and 4) not demented according to DSM-III- R criteria.

Yet another pre-demented state is describe in Graham et al., *Prevalence and  
25 severity of cognitive impairment with and without dementia in an elderly population*, Lancet 349:1793-6 (1997).

A pre-demented state may also be evaluated using a measurement of vascular cognitive impairment which is described by Wentzel *et al.*, *Progression of impairment in patients with vascular cognitive impairment without dementia*, Neurology 2001;57:714-6  
30 (2001). In this study, it was found that the 46% of the participants found to have vascular CIND developed dementia.

In carrying out the present invention, a clinician would for example use one of the above methods to determine if a patient is at risk for developing dementia. In another aspect of the present invention, a patient found to fit the criteria for a pre-demented condition, *e.g.*, as defined above, would be a particular example of a patient suitable for administration of an effective amount of rosuvastatin. An effective amount of rosuvastatin is an amount sufficient to symptomatically relieve cognitive symptoms in a patient. This may be shown for example by a slowing of the progression or worsening of cognitive symptoms or by reducing the risk of patients with cognitive symptoms from getting worse (progressing to dementia).

Practitioners may use known methods to optimise the use of rosuvastatin to prevent dementia. For example, skilled practitioners may use clinical studies as a method to maximise the efficacy of the drug. Accordingly, the dose and therapeutic effect of rosuvastatin may be demonstrated by conventional controlled clinical trials in subjects with a pre-demented condition. The therapeutic effect of rosuvastatin in these patients will be shown via symptomatic relief of cognitive symptoms, slowing of progression of worsening cognitive symptoms, or reducing the risk of patients with cognitive symptoms from getting worse (progressing to dementia or worsening degree of dementia).

Rosuvastatin can be administered orally or parentally using known methods. If orally administered, rosuvastatin may be provided in the form of a tablet, powder, capsules, granules, aqueous or oily suspensions or liquid form such as syrup or elixir. If parenterally administered, it may typically be provided in the form of an aqueous or oily suspension. Conventional methods may be used to formulate rosuvastatin or its pharmaceutically acceptable salt for example, excipients, binders, lubricants, aqueous or oily solubilizers, emulsifiers, and suspending agents. Preservatives and stabilizers can be further used.

Preferred formulation may be found for example in PCT application No.: WO 01/54668, incorporated herein by reference. The dosage would vary with the administration route, age, weight, condition, and the kind of disease of the patients, but would typically be 0.5 – 200 mg/day. If an oral dosage form is used a dosage of 1-100mg/day, preferably 1 – 80 mg/day would be used. If given parentally, the dosage may be 0.5 – 50 mg/day. The dosage may be given in single or divided doses. A typical dosing regimen for rosuvastatin would be oral once a day from 1 to 80 mg in patients.

Studies in the mouse have demonstrated that subcutaneous administration of 2 or 20 mg/kg of rosuvastatin (calcium salt) for 14 days increased the expression and activity of eNOS and reduced the volume of infarct resulting from a subsequent cerebral ischemia caused by middle-cerebral artery occlusion (MCAO). The studies were generally carried out according to the methods set forth in M. Endres *et al.*, *Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase*, Proc. Natl. Acad. Sci. USA, 95:8880-8885 (1998). In many cases dementia is known to result from the cumulative neurodegenerative effects of strokes. These can be major strokes or sub-clinical strokes, and result in a heterogeneous group of dementias commonly called vascular dementia (VAD). In this study rosuvastatin protected the brain in mice from cerebral ischemia. A mechanism by which rosuvastatin may prevent dementia is by protecting the brain from cerebral ischemia.

While not wishing to be bound by any theory it is believed that there are several mechanisms of action whereby rosuvastatin might prevent dementia. Endothelial nitric oxide synthase (eNOS) is expressed by endothelial cells of the arterial vasculature. eNOS liberates nitric oxide (NO) by converting the amino acid arginine to citrulline. NO causes relaxation of vascular smooth muscle closely apposed to the endothelial cells, and is thus a potent vasodilating agent. Dilation of cerebral vasculature leads to increased cerebral blood flow and protects the brain from ischemic insults.

Mutations in the genes for the amyloid precursor protein (APP) and presenilin-1 (PS-1) cause increased brain levels of the peptide amyloid- $\beta$  ( $A\beta$ ), and are the cause of familial Alzheimer's Dementia (fAD). The brains of Alzheimer's patients lacking mutations in these genes exhibit fibrillar plaques largely composed of  $A\beta$ , just as do the brains of fAD patients. Thus, increased levels of  $A\beta$  in the brain is thought to cause both the deposition of  $A\beta$  into plaques (amyloidosis) and Alzheimer's Dementia (AD). The majority of demented patients exhibit evidence of both amyloidosis and cerebral ischemia. In fact, patients diagnosed with probable AD who died with both amyloid plaques and evidence of minor vascular ischemia (small "lacunar" infarcts), had much worse cognitive function than other patients with the same number of amyloid plaques. Thus, by protecting against cerebral ischemia by the mechanism described above, rosuvastatin may prevent both VAD, AD, and mixed AD/VAD.

Another mechanism by which rosuvastatin might prevent dementia is by reducing brain A $\beta$  levels. One mechanism whereby rosuvastatin might reduce brain A $\beta$  levels is by increasing the removal of A $\beta$  from the brain. The cell-surface receptor LRP-1 (LDL receptor related protein-1) has been shown to mediate the transport of A $\beta$  bound to the LRP-1 ligands apolipoprotein E (ApoE) and  $\beta$ -2 macroglobulin ( $\beta$ 2M). Polymorphisms associated with decreased expression of LRP-1 are have been associated with increased risk of AD. Allelic inheritance of the ApoE4 allele of the LRP-1 ligand ApoE has also been linked to an increased risk of AD. Further evidence suggests that LRP-1 is expressed in endothelial cells of the cerebral vasculature, and that A $\beta$  is normally extruded from the brain by transport across the endothelial cell layer dependent on the function of LRP-1. Thus LRP-1/ApoE may represent an important route for the removal of A $\beta$  from the brain. The LRP-1 gene, like the closely related LDLR gene, contains a DNA sequence called the sterol responsive element (SRE1). This gene sequence causes the transcription of a gene to be responsive to cellular levels of sterols related to cholesterol. When cell sterol levels decline, the transcription of genes containing an SRE is increased. In fact, liver LRP-1 mRNA levels have been shown to increased following administration of a cholesterol-lowering dose of a statin. Rosuvastatin decreases the biosynthesis of cholesterol. By reducing the biosynthesis of cholesterol, rosuvastatin may decrease endothelial cell sterol levels, thereby increasing the transcription of the LRP-1 gene. The resulting increased expression of the LRP-1 cell-surface receptor may increase the ligand-mediated extrusion of A $\beta$  from the brain. Statins are further known to increase expression of ApoE. Increased expression of ApoE could further increase ApoE/LRP-1 mediated extrusion of A $\beta$  from the brain. Thus another mechanism by which rosuvastatin may prevent dementia is by increasing LRP-1/ApoE dependent extrusion of A $\beta$  from the brain.

Rosuvastatin has been shown to be superior to other coenzyme A (HMG-CoA) reductase inhibitors in reducing cholesterol in patients which is unexpected particularly in its ability to prevent dementia. Thus, it is surprising and unexpected that rosuvastatin provides a method for preventing dementia in a patient at risk of developing dementia such as patients shown to have an observed pre-demented state.

**CLAIMS**

We claim:

5

1. A method of preventing dementia in a patient comprising administering to a patient at risk of developing dementia an effective amount of rosuvastatin or its pharmaceutically acceptable salt.

10

2. Use of rosuvastatin or its pharmaceutically acceptable salt for the manufacture of a medicament for administration to a patient at risk of developing dementia.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/01911

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/505, A61P 25/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, CHEM. ABS DATA, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	Akt Neurol, Volume 29, No. 5, June 2002, J. Bösel et al: "Einsatz der Statine in der Neurologie", page 254 - page 261, page 254, abstract; page 255, left column; page 258, right column second paragraph - page 259, left column first paragraph --	1,2
P,Y	The Journal of Clinical Investigation, Volume 110, No. 3, August 2002, James K. Liao, "Isoprenoids as mediators of the biological effects of statins", page 285 - page 288, page 285, right column, second paragraph, page 287, right column, second paragraph --	1-2
P,Y	Nature Medicine, Volume 8, No. 6, June 2002, Laura Bonetta: "Potential neurological value of statins increases", page 541 - page 541 --	1-2

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

16 January 2003

Date of mailing of the international search report

17 -01- 2003

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Gerd Strandell/Eö  
Telephone No. +46 8 782 25 00



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/01911

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5260440 A (KENTARO HIRAI ET AL), 9 November 1993 (09.11.93)  --	1-2
Y	Bioorganic & Medicinal Chemistry, Volume 5, No. 2, 1997, Masamichi Watanabe et al: "Synthesis and Biological Activity of Methanesulfonamide Pyrimidine- and N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors", page 437 - page 444  --	1-2
Y	WO 0045819 A1 (ASTRAZENECA UK LIMITED), 10 August 2000 (10.08.00)  --	1-2
Y	The Lancet, Volume 356, November 2000, H Jick et al: "Statins and the risk of dementia", page 1627 - page 1631  --	1-2
Y	STN International, File EMBASE, EMBASE accession no. 2000364323, Wolozin B. et al: "Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors"; & Archives of Neurology, (2000) 57/10 (1439-1443)  --	1-2
Y	STN International, File EMBASE, EMBASE accession no. 2001331088, Simons M. et al: "Cholesterol and Alzheimer's disease: Is there a link?"; & Neurology, (25 Sep 2001) 57/6 (1089-1093)  --	1-2
A	Neurobiology of Aging, Volume 17, No. 2, 1996, D. Larry Sparks: "Intraneuronal Beta-Amyloid Immunoreactivity in the CNS", page 291 - page 299  -- -----	1-2

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE 02/01911

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see next sheet**
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE 02/01911

Claim 1 relates to a method of treatment of the human or animal body by surgery or by therapy/a diagnostic method practised on the human or animal body/Rule 39.1(iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compound/composition.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

30/12/02

International application No.

PCT/SE 02/01911

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
US	5260440	A	09/11/93	AT	197149 T	15/11/00
				CA	2072945 A	02/01/93
				DE	69231530 D,T	13/06/01
				DK	521471 T	05/02/01
				EP	0521471 A,B	07/01/93
				SE	0521471 T3	
				ES	2153824 T	16/03/01
				GR	3035189 T	30/04/01
				HK	1011986 A	00/00/00
				HU	61531 A	28/01/93
				HU	219407 B	28/04/01
				HU	220624 B	28/03/02
				HU	0004863 D	00/00/00
				HU	9202179 D	00/00/00
				JP	2648897 B	03/09/97
				JP	5178841 A	20/07/93
				KR	9605951 B	06/05/96
				PT	521471 T	30/04/01
				US	RE37314 E	07/08/01
WO	0045819	A1	10/08/00	AU	2305100 A	25/08/00
				AU	5428899 A	28/02/00
				BR	0007991 A	06/11/01
				CA	2337861 A	17/02/00
				CN	1347320 T	01/05/02
				CZ	20012631 A	17/10/01
				EE	200100404 A	15/10/02
				EP	1102849 A	30/05/01
				EP	1150679 A	07/11/01
				GB	9902590 D	00/00/00
				HU	0105019 A	29/05/02
				IL	144662 D	00/00/00
				JP	2002524044 T	06/08/02
				JP	2002536333 T	29/10/02
				NO	20013810 A	03/10/01
				PL	349137 A	01/07/02
				SK	11112001 A	05/02/02
				TR	200102236 T	00/00/00
				GB	9921062 D	00/00/00